RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1600 participants.

Also called NCT07187570

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07187570
  • EU CT 2024-513719-28-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07187570. Randomized; single masking; primary purpose treatment. Start 2025-06-03 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Acronym
RECUR-AF
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Dapagliflozin 10 mg once daily
Lead sponsor
Region Stockholm (class: other government)
Collaborator
Karolinska Institutet (class: other)

Record details

Record id
cardio:ct-nct07187570
Content hash
0c2a29338bf69dead9da6ab8122dcb40b995986a87746911bdbfe6203a2776bc